Patent Reports Sample Clauses

Patent Reports. At the end of each Collaboration Year during the term of this Agreement, each party shall provide the Patent Committee with a report, in form and substance to be determined by the Patent Committee, identifying (i) patent applications comprising any Evogene Patent Rights, Evogene Discovery Round Patent Rights or Evogene G2P Round Patent Rights that were filed during the preceding year and the prosecution status of all previously-filed patent applications comprising Evogene Patent Rights, Evogene Discovery Round Patent Rights or Evogene G2P Round Patent Rights, and (ii) (A) for the first such report after the date that any Excluded Collaboration Hit or Excluded PlaNet Xxxx Xxxxx arises, patent applications comprising any Monsanto Improvement Patent Rights covering such Excluded Collaboration Hit or Excluded PlaNet Xxxx Xxxxx and the prosecution status thereof, and (B) for each subsequent year after an Excluded Collaboration Hit or Excluded PlaNet Xxxx Xxxxx arises, all patent applications comprising any Monsanto Improvement Patent Rights covering such Excluded Collaboration Hit or Excluded PlaNet Xxxx Xxxxx that were filed during the preceding year and the prosecution status of all previously-filed patent applications comprising any Monsanto Improvement Patent Rights covering such Excluded Collaboration Hit or Excluded PlaNet Xxxx Xxxxx.
AutoNDA by SimpleDocs
Patent Reports. All DOTC Base Agreements shall require the use of DD Form 882, Report of Inventions and Subcontracts, to file an invention report for every OTIA. Negative reports are also required. The NAC Member shall provide the CMF, with an Annual Invention Report at the close of each performance year of each OTIA and at the end of the term of each OTIA.
Patent Reports. The Consortium or Consortium Members shall file Invention (Patent) Reports as of the close of the performance year and at the end of each project award for this Agreement or more frequently if a statutory bar will occur before the next annual or final project report. Annual reports are due sixty (60) calendar days after the expiration of the final performance period. The Research Project Awardee shall use DD Form 882, Report of Inventions and Subawards (or forms appropriate to non DoD agencies), to file an invention report. Such reports are required whether or not a Subject Invention was made. The patent recipient Consortium Member(s) shall submit the original and one copy to the AO, through the CM, and one copy to the technology scientist or engineer. Authorization and Consent. The Government authorizes and consents under 28 U.S.C. 1498 to all use and manufacture of any invention described in and covered by a United States patent in the performance of this Agreement or any subaward at any tier. Final Payment. Final payment cannot be made nor can the Agreement be closed-out until the patent recipient, Consortium or Consortium Members deliver to the Government all disclosures of Subject Inventions required by this Agreement, an acceptable final report pursuant to the article entitled “Reports,” and all confirmatory instruments.
Patent Reports. The Consortium or Consortium Members shall file Invention (Patent) Reports as of the close of the performance year and at the end of each project award for this Agreement or more frequently if a statutory bar will occur before the next annual or final project report. Annual reports are due sixty (60) calendar days after the expiration of the final performance period. The Researc Project Awardee shall use DD Form 882, Report of Inventions and Subawards (or forms appropriate to non DoD agencies), to file an invention report. Such reports are required whether or not a Subject Invention was made. The patent recipient Consortium Member(s) shall submit the original and one copy to the AO, through the CM, and one copy to the technology scientist or engineer.
Patent Reports. Seller shall file Invention (Patent) Reports at the close of the performance year and at the end of the term of this Contract. Annual reports are due thirty (30) calendar days after the expiration of the final performance period. Seller shall use the DD Form 882, Report of Inventions and Subcontracts, to file an invention report. Negative reports are also required. Seller shall contact Xxxxx’s Authorized Procurement Representative to obtain the name and address of the Government representative for the required reports. Seller shall also submit one copy to Xxxxx’s Authorized Procurement Representative.
Patent Reports. At the end of each calendar year during the term of this Agreement, the Patent Committee shall prepare a report, in form and substance to be determined by the Patent Committee, identifying the patent applications comprising Joint IP, Biotectix Technology, or Acutus Technology that were filed during the preceding calendar year and the prosecution status of all previously-filed patent applications comprising Joint IP, Biotectix Technology, or Acutus Technology.
Patent Reports. The recipient shall utilize DD Form 882, Report of Inventions and Subcontracts, for submission of interim and final invention reports. The DD Form 882 and all invention disclosures shall be submitted to the Administrative Agreements Officer for proper disposition and forwarding to the Agreements Officer.
AutoNDA by SimpleDocs
Patent Reports. Property Reports: (Other reporting as may be dictated by your prime) Reports: All reports to Sponsor are due within 60 days after expiration or termination of the Agreement other than for material breach by Sponsor, extendable for 90 days by Principal Investigator with consent by the Sponsor Technical Representative, which the Sponsor Technical Representative may not unreasonably withhold.
Patent Reports. The Consortium or Consortium Members shall disclose each Subject Invention and shall file a final Invention Report at the end of each project award for this Agreement. The Research Project Awardee shall use DD Form 882, Report of Inventions and Subawards (or forms appropriate to non DoD agencies), to file an invention report. Final reports are required whether or not a Subject Invention was made. The Consortium Member(s) shall submit a copy to the CM who will in turn provide a copy to the AO and SOTR. As reporting through iEdison is not required, Research Project Awardees shall not utilize this online database system for any patent or inventions reporting related specifically to awards made through the MTEC consortium. Authorization and Consent. The Government authorizes and consents under 28 U.S.C. 1498 to all use and manufacture of any invention described in and covered by a United States patent in the performance of this Agreement or any subaward at any tier. Final Payment. Final payment cannot be made nor can the Agreement be closed-out until the Consortium or Consortium Members deliver to the Government acceptable final report(s) pursuant to the article titled “Reports,” and all confirmatory instruments.

Related to Patent Reports

  • Development Reports Beginning six months after Effective Date and ending on the date of first commercial sale of a Licensed Product in the United States, LICENSEE shall report to Cornell progress covering LICENSEE's (and Affiliate's and Sublicensee's) activities and efforts in the development of rights granted to LICENSEE under this Agreement for the preceding six months. The report shall include, but not be limited to, activities and efforts to develop and test all Licensed Products and obtain governmental approvals necessary for marketing the same. Such semi-annual reports shall be due within sixty days (60) of the reporting period and shall use the form as provided herein as Appendix C.

  • Adverse Event Reporting Both Parties acknowledge the obligation to comply with the Protocol and / or applicable regulations governing the collection and reporting of adverse events of which they may become aware during the course of the Clinical Trial. Both Parties agree to fulfil and ensure that their Agents fulfil regulatory requirements with respect to the reporting of adverse events.

  • Patent Listings Licensee shall have the right and responsibility to make all filings with Regulatory Authorities in the Territory with respect to the AstraZeneca Patents, including as required or allowed (i) in the United States, in the FDA’s Orange Book and (ii) in the European Union, under the national implementations of Article 10.1(a)(iii) of Directive 2001/EC/83 or other international equivalents; provided that Licensee shall consult with AstraZeneca to determine the course of action with respect to such filings.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!